COVID‐19 Clinical Diagnostics and Testing Technology

Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacotherapy 2020-08, Vol.40 (8), p.857-868
Hauptverfasser: Chau, Cindy H., Strope, Jonathan D., Figg, William D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 868
container_issue 8
container_start_page 857
container_title Pharmacotherapy
container_volume 40
creator Chau, Cindy H.
Strope, Jonathan D.
Figg, William D.
description Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID‐19 diagnostics on the horizon. Antibody response against SARS‐CoV‐2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.
doi_str_mv 10.1002/phar.2439
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7361586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2437267931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4439-8d8d483e42a00f11af0d3506f651d85f74b8e0155607a0c9cd0c48706ca4136b3</originalsourceid><addsrcrecordid>eNp1kctKAzEUhoMoWi8LX0AKbnQxenKZJLMRpF4qFCqibkOaybSRaVInVunOR_AZfRJTW0UFV-fA-fLxnxyEdjEcYQByPBnp5ogwWqygFpYizwqM2SpqAREiAwC5gTZjfEgo5oysow1KOKMEyxbinf791dn76xsu2p3aeWd03T5zeuhDfHImtrUv27c29X6Yqhn5UIfhbButVbqOdmdZt9Ddxfltp5v1-pdXndNeZliKk8lSlkxSy4gGqDDWFZQ0B17xHJcyrwQbSAs4zzkIDaYwJRgmBXCjGaZ8QLfQycI7mQ7GtjTWPzW6VpPGjXUzU0E79Xvi3UgNw7MSlONc8iQ4WAqa8DhNe6ixi8bWtfY2TKMijBAAWlCR0P0_6EOYNj6tlygqCBcFxYk6XFCmCTE2tvoOg0HNr6Hm15i_KBK79zP9N_n1_Qk4XgAvrraz_03qunt686n8AHM1kxc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2437267931</pqid></control><display><type>article</type><title>COVID‐19 Clinical Diagnostics and Testing Technology</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Chau, Cindy H. ; Strope, Jonathan D. ; Figg, William D.</creator><creatorcontrib>Chau, Cindy H. ; Strope, Jonathan D. ; Figg, William D.</creatorcontrib><description>Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID‐19 diagnostics on the horizon. Antibody response against SARS‐CoV‐2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.</description><identifier>ISSN: 0277-0008</identifier><identifier>EISSN: 1875-9114</identifier><identifier>DOI: 10.1002/phar.2439</identifier><identifier>PMID: 32643218</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>antibody ; Antibody response ; antigen ; Betacoronavirus ; Clinical Laboratory Techniques ; Clinical Protocols ; Coronaviridae ; Coronavirus Infections - diagnosis ; Coronaviruses ; COVID-19 ; COVID-19 Testing ; Diagnostic Errors ; Humans ; Pandemics ; Pneumonia, Viral - diagnosis ; Point-of-Care Systems ; Real-Time Polymerase Chain Reaction ; Regular Manuscripts ; RT‐PCR ; SARS-CoV-2 ; Sensitivity and Specificity ; Serologic Tests - methods ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Special ; World Health Organization</subject><ispartof>Pharmacotherapy, 2020-08, Vol.40 (8), p.857-868</ispartof><rights>2020 Pharmacotherapy Publications, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4439-8d8d483e42a00f11af0d3506f651d85f74b8e0155607a0c9cd0c48706ca4136b3</citedby><cites>FETCH-LOGICAL-c4439-8d8d483e42a00f11af0d3506f651d85f74b8e0155607a0c9cd0c48706ca4136b3</cites><orcidid>0000-0003-2428-5613</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fphar.2439$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fphar.2439$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32643218$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chau, Cindy H.</creatorcontrib><creatorcontrib>Strope, Jonathan D.</creatorcontrib><creatorcontrib>Figg, William D.</creatorcontrib><title>COVID‐19 Clinical Diagnostics and Testing Technology</title><title>Pharmacotherapy</title><addtitle>Pharmacotherapy</addtitle><description>Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID‐19 diagnostics on the horizon. Antibody response against SARS‐CoV‐2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.</description><subject>antibody</subject><subject>Antibody response</subject><subject>antigen</subject><subject>Betacoronavirus</subject><subject>Clinical Laboratory Techniques</subject><subject>Clinical Protocols</subject><subject>Coronaviridae</subject><subject>Coronavirus Infections - diagnosis</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Testing</subject><subject>Diagnostic Errors</subject><subject>Humans</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - diagnosis</subject><subject>Point-of-Care Systems</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Regular Manuscripts</subject><subject>RT‐PCR</subject><subject>SARS-CoV-2</subject><subject>Sensitivity and Specificity</subject><subject>Serologic Tests - methods</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Special</subject><subject>World Health Organization</subject><issn>0277-0008</issn><issn>1875-9114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctKAzEUhoMoWi8LX0AKbnQxenKZJLMRpF4qFCqibkOaybSRaVInVunOR_AZfRJTW0UFV-fA-fLxnxyEdjEcYQByPBnp5ogwWqygFpYizwqM2SpqAREiAwC5gTZjfEgo5oysow1KOKMEyxbinf791dn76xsu2p3aeWd03T5zeuhDfHImtrUv27c29X6Yqhn5UIfhbButVbqOdmdZt9Ddxfltp5v1-pdXndNeZliKk8lSlkxSy4gGqDDWFZQ0B17xHJcyrwQbSAs4zzkIDaYwJRgmBXCjGaZ8QLfQycI7mQ7GtjTWPzW6VpPGjXUzU0E79Xvi3UgNw7MSlONc8iQ4WAqa8DhNe6ixi8bWtfY2TKMijBAAWlCR0P0_6EOYNj6tlygqCBcFxYk6XFCmCTE2tvoOg0HNr6Hm15i_KBK79zP9N_n1_Qk4XgAvrraz_03qunt686n8AHM1kxc</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Chau, Cindy H.</creator><creator>Strope, Jonathan D.</creator><creator>Figg, William D.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2428-5613</orcidid></search><sort><creationdate>202008</creationdate><title>COVID‐19 Clinical Diagnostics and Testing Technology</title><author>Chau, Cindy H. ; Strope, Jonathan D. ; Figg, William D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4439-8d8d483e42a00f11af0d3506f651d85f74b8e0155607a0c9cd0c48706ca4136b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>antibody</topic><topic>Antibody response</topic><topic>antigen</topic><topic>Betacoronavirus</topic><topic>Clinical Laboratory Techniques</topic><topic>Clinical Protocols</topic><topic>Coronaviridae</topic><topic>Coronavirus Infections - diagnosis</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Testing</topic><topic>Diagnostic Errors</topic><topic>Humans</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - diagnosis</topic><topic>Point-of-Care Systems</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Regular Manuscripts</topic><topic>RT‐PCR</topic><topic>SARS-CoV-2</topic><topic>Sensitivity and Specificity</topic><topic>Serologic Tests - methods</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Special</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chau, Cindy H.</creatorcontrib><creatorcontrib>Strope, Jonathan D.</creatorcontrib><creatorcontrib>Figg, William D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chau, Cindy H.</au><au>Strope, Jonathan D.</au><au>Figg, William D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID‐19 Clinical Diagnostics and Testing Technology</atitle><jtitle>Pharmacotherapy</jtitle><addtitle>Pharmacotherapy</addtitle><date>2020-08</date><risdate>2020</risdate><volume>40</volume><issue>8</issue><spage>857</spage><epage>868</epage><pages>857-868</pages><issn>0277-0008</issn><eissn>1875-9114</eissn><abstract>Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID‐19 diagnostics on the horizon. Antibody response against SARS‐CoV‐2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32643218</pmid><doi>10.1002/phar.2439</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-2428-5613</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0277-0008
ispartof Pharmacotherapy, 2020-08, Vol.40 (8), p.857-868
issn 0277-0008
1875-9114
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7361586
source MEDLINE; Wiley Online Library
subjects antibody
Antibody response
antigen
Betacoronavirus
Clinical Laboratory Techniques
Clinical Protocols
Coronaviridae
Coronavirus Infections - diagnosis
Coronaviruses
COVID-19
COVID-19 Testing
Diagnostic Errors
Humans
Pandemics
Pneumonia, Viral - diagnosis
Point-of-Care Systems
Real-Time Polymerase Chain Reaction
Regular Manuscripts
RT‐PCR
SARS-CoV-2
Sensitivity and Specificity
Serologic Tests - methods
Serology
Severe acute respiratory syndrome coronavirus 2
Special
World Health Organization
title COVID‐19 Clinical Diagnostics and Testing Technology
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T19%3A42%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID%E2%80%9019%20Clinical%20Diagnostics%20and%20Testing%20Technology&rft.jtitle=Pharmacotherapy&rft.au=Chau,%20Cindy%20H.&rft.date=2020-08&rft.volume=40&rft.issue=8&rft.spage=857&rft.epage=868&rft.pages=857-868&rft.issn=0277-0008&rft.eissn=1875-9114&rft_id=info:doi/10.1002/phar.2439&rft_dat=%3Cproquest_pubme%3E2437267931%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2437267931&rft_id=info:pmid/32643218&rfr_iscdi=true